Segall Bryant & Hamill LLC Cuts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)

Segall Bryant & Hamill LLC decreased its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 1.3% during the 4th quarter, Holdings Channel reports. The fund owned 71,500 shares of the biopharmaceutical company’s stock after selling 951 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in Cytokinetics were worth $3,363,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in CYTK. Vanguard Group Inc. boosted its holdings in Cytokinetics by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company’s stock valued at $560,520,000 after purchasing an additional 154,216 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cytokinetics by 4.0% in the 3rd quarter. Geode Capital Management LLC now owns 2,848,584 shares of the biopharmaceutical company’s stock valued at $150,433,000 after buying an additional 109,938 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Cytokinetics by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,335,189 shares of the biopharmaceutical company’s stock valued at $62,807,000 after buying an additional 13,798 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Cytokinetics by 17.2% during the third quarter. Janus Henderson Group PLC now owns 1,143,830 shares of the biopharmaceutical company’s stock worth $60,399,000 after acquiring an additional 167,501 shares during the period. Finally, Fisher Asset Management LLC raised its position in Cytokinetics by 13.7% in the fourth quarter. Fisher Asset Management LLC now owns 616,492 shares of the biopharmaceutical company’s stock worth $29,000,000 after acquiring an additional 74,208 shares in the last quarter.

Cytokinetics Price Performance

NASDAQ:CYTK opened at $42.99 on Friday. Cytokinetics, Incorporated has a 12-month low of $40.53 and a 12-month high of $75.71. The firm has a market cap of $5.09 billion, a price-to-earnings ratio of -7.99 and a beta of 0.95. The company’s 50-day moving average is $45.80 and its two-hundred day moving average is $49.67. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.03. The firm had revenue of $16.93 million for the quarter, compared to analysts’ expectations of $14.26 million. Research analysts expect that Cytokinetics, Incorporated will post -5.24 EPS for the current year.

Analyst Ratings Changes

CYTK has been the topic of a number of recent analyst reports. Citigroup assumed coverage on shares of Cytokinetics in a research note on Friday, February 7th. They set a “buy” rating and a $86.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a “buy” rating and a $80.00 target price on the stock. Evercore ISI upgraded shares of Cytokinetics to a “strong-buy” rating in a research report on Friday, February 7th. JMP Securities restated a “market outperform” rating and issued a $78.00 price target on shares of Cytokinetics in a report on Friday, February 7th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 price objective on shares of Cytokinetics in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $82.00.

Insiders Place Their Bets

In other news, CEO Robert I. Blum sold 16,970 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $43.44, for a total transaction of $737,176.80. Following the completion of the transaction, the chief executive officer now owns 364,181 shares of the company’s stock, valued at $15,820,022.64. This represents a 4.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $49.32, for a total transaction of $98,640.00. Following the transaction, the executive vice president now owns 116,071 shares in the company, valued at approximately $5,724,621.72. The trade was a 1.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,834 shares of company stock valued at $1,949,275 in the last quarter. 3.40% of the stock is currently owned by company insiders.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.